Thalidomide decreases high glucose‑induced extracellular matrix protein synthesis in mesangial cells via the AMPK pathway

Zhang,Hong‑Xia; Yuan,Jie; Li,Ya‑Feng; Li,Rong‑Shan

doi:10.3892/etm.2018.6995

Thalidomide decreases high glucose‑induced extracellular matrix protein synthesis in mesangial cells via the AMPK pathway

Authors:
- Hong‑Xia Zhang
- Jie Yuan
- Ya‑Feng Li
- Rong‑Shan Li
View Affiliations

Affiliations: Department of Nephrology, The Affiliated People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Taiyuan, Shanxi 030012, P.R. China, Department of Radiology, The Affiliated People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Taiyuan, Shanxi 030012, P.R. China
Published online on: November 20, 2018 https://doi.org/10.3892/etm.2018.6995
Pages: 927-934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous study demonstrated the renal‑protective effect of thalidomide (Thd) in diabetic nephropathy rats through the activation of the adenosine monophosphate‑activated protein kinase (AMPK) and inhibition of the nuclear factor κB (NF‑κB)/monocyte chemoattractant protein‑1 (MCP‑1) and transforming growth factor (TGF)‑β1/mothers against decapentaplegic homolog signaling pathways. The association between AMPK inactivation and high glucose (HG)‑induced meningeal cell (MC) proliferation and extracellular matrix (ECM) accumulation via NF‑κB and TGF‑β1 signaling remains unknown. The aim of the current study was to demonstrate the effects of Thd on cell proliferation and ECM expression in HG‑cultured MCs and the underlying mechanisms. HG‑cultured human MCs were treated with Thd. Cell proliferation was measured by MTT assay and quantification of cell proliferation was based on the measurement of bromodeoxyuridine incorporation. The differences in TGF‑β1, fibronectin and MCP‑1 protein expression levels were detected via ELISA and western blot analysis. The AMPK signaling pathway was also examined by western blot analysis in MCs. Compound C, an AMPK inhibitor and AICAR (5‑aminoimidazole‑4‑carboxamide 1β‑D‑ribofuranoside), an AMPK agonist, were used to analyze the functional role of AMPK in MCs. Cell proliferation was significantly decreased in HG‑cultured MCs following treatment with high concentrations of Thd (100 and 200 µg/ml) for 24 h compared with the HG‑cultured MC group. Thd suppressed the inflammatory processes in HG‑induced MCs. These effects were partially mediated through the activation of AMPK and inhibition of the NF‑κB/MCP‑1 signaling pathways. Taken together, these results suggest that Thd may have therapeutic potential in diabetic renal injury via the AMPK signaling pathway.

View Figures

View References

1	International Diabetes Federation: IDF Diabetes Atlas 7th edition (2015). https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.htmlAugust 14–2018
2	Kolset SO, Reinholt FP and Jenssen T: Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 60:976–986. 2012. View Article : Google Scholar : PubMed/NCBI
3	Mason RM and Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 14:1358–1373. 2003. View Article : Google Scholar : PubMed/NCBI
4	Wada J and Makino H: Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 124:139–152. 2013. View Article : Google Scholar : PubMed/NCBI
5	Navarro-González JF, Mora-Fernández C, de Fuentes Morus M and García-Pérez J: Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 7:327–340. 2011. View Article : Google Scholar : PubMed/NCBI
6	Min D, Lyons JG, Bonner J, Twigg SM, Yue DK and McLennan SV: Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: Possible pathogenic role in diabetic nephropathy. Am J Physiol Renal Physiol. 297:F1229–F1237. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ingaramo PI, Ronco MT, Francés DE, Monti JA, Pisani GB, Ceballos MP, Galleano M, Carrillo MC and Carnovale CE: Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes Mellitus. Mol Immunol. 48:1397–1407. 2011. View Article : Google Scholar : PubMed/NCBI
8	Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G and Gruden G: Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia. 51:198–207. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, et al: AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans. 31:162–168. 2003. View Article : Google Scholar : PubMed/NCBI
10	Decleves AE, Mathew AV, Cunard R and Sharma K: AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol. 22:1846–1855. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hallows KR, Mount PF, Pastor-Soler NM and Power DA: Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am JPhysiol Renal Physiol. 298:F1067–F1077. 2010. View Article : Google Scholar
12	Lv ZM, Liu Y, Zhang PJ, Xu J, Jia ZH, Wang R and Wan Q: The role of AMPKα in high glucose-induced dysfunction of cultured rat mesangial cells. Ren Fail. 34:616–621. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D and Zou MH: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: Role of 26S proteasomes. Circ Res. 106:1117–1128. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Ko SH, Shin SJ, Choi BS, et al: Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-Sirt1-PGC1α axis in db/db mice. Diabetologia. 56:204–217. 2013. View Article : Google Scholar : PubMed/NCBI
15	Salminen A, Hyttinen JM and Kaarniranta K: AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl). 89:667–676. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS and Lee SK: AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 304:F686–F697. 2013. View Article : Google Scholar : PubMed/NCBI
17	Raje N and Anderson K: Thalidomide - a revival story. N Engl J Med. 341:1606–1609. 1999. View Article : Google Scholar : PubMed/NCBI
18	Asher C and Furnish T: Lenalidomide and thalidomide in the treatment of chronic pain. Expert Opin Drug Saf. 12:367–374. 2013. View Article : Google Scholar : PubMed/NCBI
19	Amirshahrokhi K and Ghazi-Khansari M: Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines. Cytokine. 60:522–527. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhao J, Wang H, Song T, Yang Y, Gu K, Ma P, Zhang Z, Shen L, Liu J and Wang W: Thalidomide promotes morphine efficacy and prevents morphine-induced tolerance in rats with diabetic neuropathy. Neurochem Res. 41:3171–3180. 2016. View Article : Google Scholar : PubMed/NCBI
21	Behl T, Kaur I, Goel H and Kotwani A: Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. Vascul Pharmacol. 92:6–15. 2017. View Article : Google Scholar : PubMed/NCBI
22	Kim DH, Kim YJ, Chang SA, Lee HW, Kim HN, Kim HK, Chang HJ, Sohn DW and Park YB: The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy. Eur J Heart Fail. 12:1051–1060. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Yang Y, Wang Y, Wang B and Li R: Renal-protective effect of thalidomide in streptozotocin-induced diabetic rats through anti-inflammatory pathway. Drug Des Devel Ther. 12:89–98. 2018. View Article : Google Scholar : PubMed/NCBI
24	Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y and Xue YM: Exendin-4 alleviateshigh glucose-induced rat mesangial cell dysfunction throughthe AMPK pathway. Cell Physiol Biochem. 33:423–432. 2014. View Article : Google Scholar : PubMed/NCBI
25	García-García PM, Getino-Melián MA, Domínguez-Pimentel V and Navarro-González JF: Inflammation in diabetic kidney disease. World J Diabetes. 5:431–443. 2014. View Article : Google Scholar : PubMed/NCBI
26	Williams MD and Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 7:242–248. 2007. View Article : Google Scholar : PubMed/NCBI
27	Tesch GH: MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 294:F697–F701. 2008. View Article : Google Scholar : PubMed/NCBI
28	Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M and Ito S: Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications. 17:11–15. 2003. View Article : Google Scholar : PubMed/NCBI
29	Cheng J, Encarnacion Diaz MM, Warner GM, Gray CE, Nath KA and Grande JP: TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am J Physiol Cell Physiol. 289:C959–C970. 2005. View Article : Google Scholar : PubMed/NCBI
30	Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG and Kasinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 292:F617–F627. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhao J, Miyamoto S, You YH and Sharma K: AMP-activated protein kinase (AMPK) activation inhibits nuclear translocation of Smad4 in mesangial cells and diabetic kidneys. Am J Physiol Renal Physiol. 308:F1167–F1177. 2015. View Article : Google Scholar : PubMed/NCBI
32	Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, Andreyev A, Quach T, Ly S, Shekhtman G, et al: AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 123:4888–4899. 2013. View Article : Google Scholar : PubMed/NCBI